Oberweis Asset Management Inc. Acquires 162,700 Shares of Evolus, Inc. (NASDAQ:EOLS)

Oberweis Asset Management Inc. grew its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 31.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 677,600 shares of the company's stock after buying an additional 162,700 shares during the quarter. Oberweis Asset Management Inc. owned approximately 1.07% of Evolus worth $7,481,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. KBC Group NV acquired a new stake in Evolus during the 4th quarter valued at $49,000. IFP Advisors Inc increased its stake in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after buying an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus in the fourth quarter valued at $106,000. Quantbot Technologies LP bought a new position in shares of Evolus in the fourth quarter valued at about $118,000. Finally, Tradition Wealth Management LLC grew its stake in shares of Evolus by 18.2% during the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock valued at $144,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

Insider Activity at Evolus

In other Evolus news, insider Rui Avelar sold 27,904 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares in the company, valued at $4,806,312.42. This represents a 7.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Karah Herdman Parschauer sold 12,888 shares of Evolus stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the sale, the director now owns 32,183 shares of the company's stock, valued at approximately $418,057.17. This trade represents a 28.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 60,575 shares of company stock worth $794,369 in the last 90 days. Corporate insiders own 6.10% of the company's stock.

Evolus Trading Up 3.2 %

Shares of NASDAQ:EOLS traded up $0.36 during midday trading on Tuesday, hitting $11.67. 210,079 shares of the stock were exchanged, compared to its average volume of 862,046. The stock has a market capitalization of $742.06 million, a price-to-earnings ratio of -12.83 and a beta of 0.97. The business's 50-day moving average price is $12.18 and its 200 day moving average price is $12.86. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Barclays boosted their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. BTIG Research assumed coverage on Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 9th. Finally, HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of Evolus in a report on Thursday, April 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus currently has a consensus rating of "Buy" and a consensus price target of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.